Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Ritter J, Sander A, Schrauder A, von Stackelberg A, Starý J, Reinhardt D. Creutzig U, et al. Among authors: ritter j. Blood. 2013 Jul 4;122(1):37-43. doi: 10.1182/blood-2013-02-484097. Epub 2013 May 23. Blood. 2013. PMID: 23704089 Free article. Clinical Trial.
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D. Creutzig U, et al. Among authors: ritter j. J Clin Oncol. 2006 Sep 20;24(27):4499-506. doi: 10.1200/JCO.2006.06.5037. J Clin Oncol. 2006. PMID: 16983120 Clinical Trial.
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G; ALL-REZ BFM Study Group. von Stackelberg A, et al. Among authors: ritter j. Blood. 2008 Mar 1;111(5):2573-80. doi: 10.1182/blood-2007-07-102525. Epub 2007 Dec 18. Blood. 2008. PMID: 18089849 Free article. Clinical Trial.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M; German-Austrian-Swiss ALL-BFM Study Group. Möricke A, et al. Blood. 2008 May 1;111(9):4477-89. doi: 10.1182/blood-2007-09-112920. Epub 2008 Feb 19. Blood. 2008. PMID: 18285545 Free article. Clinical Trial.
Development of a curative treatment within the AML-BFM studies.
Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D. Creutzig U, et al. Among authors: ritter j. Klin Padiatr. 2013 May;225 Suppl 1:S79-86. doi: 10.1055/s-0033-1337968. Epub 2013 May 22. Klin Padiatr. 2013. PMID: 23700063 Review.
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, Micalizzi C, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M. Locatelli F, et al. Among authors: ritter j. Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22. Blood. 2017. PMID: 28939722 Free article. Clinical Trial. No abstract available.
1,311 results